UNSPSC 51352409: Estrogens/meprobamate

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class HS300. This VA Drug Class (HS300) classifies this compound as belonging to the group ESTROGENS.

UNSPSC 51352409 Estrogens/meprobamate is a Commodity code representing pharmaceutical products state and local health systems and cooperative purchasing alliances procure through competitive solicitation and direct-to-manufacturer arrangements. State and local governments buy these medications as part of broader pharmacy benefit programs serving employee health plans, Medicaid populations, and institutional health facilities. The issuing bodies are typically state health and human services departments and multistate cooperative purchasing organizations that aggregate demand across participating jurisdictions and member entities. Recent procurement activity shows state agencies moving toward both traditional competitive bidding for generic pharmaceuticals through wholesaler networks and exploratory direct-to-manufacturer contracting models to optimize pricing and supply chain efficiency.

The Texas Health and Human Services Commission issued an RFI (HHS0017013) in March 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, seeking information from vendors experienced in direct contracting with self-insured employers and government health plans outside traditional pharmacy benefit manager and group purchasing organization channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, posted an RFP (S1070000015802) in January 2026 with a March 26, 2026 response deadline for generic multi-source pharmaceuticals and OTC products distributed across Minnesota, Oregon, and other participating jurisdictions through authorized wholesalers AmerisourceBergen Drug Corporation (Cencora), Cardinal Health, and Morris & Dickson Co., LLC; evaluation prioritizes price competitiveness (75 percent) and compliance with cGMP and Drug Supply Chain Security Act requirements. Geographic activity centers on Texas and the Upper Midwest cooperative purchasing region, with contract effective dates in mid-2026 and administrative structures requiring vendor participation in established wholesaler networks or direct manufacturer-to-plan relationships.